The history and status of dopamine cell therapies for Parkinson's disease
Barker, Roger A LU ; Björklund, Anders LU
and Parmar, Malin
LU
(2024)
In BioEssays
- Abstract
Parkinson's disease (PD) is characterized by the loss of the dopaminergic nigrostriatal pathway which has led to the successful development of drug therapies that replace or stimulate this network pharmacologically. Although these drugs work well in the early stages of the disease, over time they produce side effects along with less consistent clinical benefits to the person with Parkinson's (PwP). As such there has been much interest in repairing this pathway using transplants of dopamine neurons. This work which began 50 years ago this September is still ongoing and has now moved to first in human trials using human pluripotent stem cell-derived dopaminergic neurons. The results of these trials are eagerly awaited although proof of... (More)
Parkinson's disease (PD) is characterized by the loss of the dopaminergic nigrostriatal pathway which has led to the successful development of drug therapies that replace or stimulate this network pharmacologically. Although these drugs work well in the early stages of the disease, over time they produce side effects along with less consistent clinical benefits to the person with Parkinson's (PwP). As such there has been much interest in repairing this pathway using transplants of dopamine neurons. This work which began 50 years ago this September is still ongoing and has now moved to first in human trials using human pluripotent stem cell-derived dopaminergic neurons. The results of these trials are eagerly awaited although proof of principle data has already come from trials using human fetal midbrain dopamine cell transplants. This data has shown that developing dopamine cells when transplanted in the brain of a PwP can survive long term with clinical benefits lasting decades and with restoration of normal dopaminergic innervation in the grafted striatum. In this article, we discuss the history of this field and how this has now led us to the recent stem cell trials for PwP.
(Less)
- author
- Barker, Roger A
LU
; Björklund, Anders
LU
and Parmar, Malin
LU
- organization
- publishing date
- 2024-07-26
- type
- Contribution to journal
- publication status
- epub
- subject
- in
- BioEssays
- article number
- e2400118
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- scopus:85199777017
- pmid:39058892
- ISSN
- 0265-9247
- DOI
- 10.1002/bies.202400118
- language
- English
- LU publication?
- yes
- additional info
- © 2024 The Author(s). BioEssays published by Wiley Periodicals LLC.
- id
- 3abcce84-1502-48cd-9c47-e2b113b16093
- date added to LUP
- 2024-08-06 08:29:02
- date last changed
- 2024-08-07 04:01:52
@article{3abcce84-1502-48cd-9c47-e2b113b16093,
abstract = {{<p>Parkinson's disease (PD) is characterized by the loss of the dopaminergic nigrostriatal pathway which has led to the successful development of drug therapies that replace or stimulate this network pharmacologically. Although these drugs work well in the early stages of the disease, over time they produce side effects along with less consistent clinical benefits to the person with Parkinson's (PwP). As such there has been much interest in repairing this pathway using transplants of dopamine neurons. This work which began 50 years ago this September is still ongoing and has now moved to first in human trials using human pluripotent stem cell-derived dopaminergic neurons. The results of these trials are eagerly awaited although proof of principle data has already come from trials using human fetal midbrain dopamine cell transplants. This data has shown that developing dopamine cells when transplanted in the brain of a PwP can survive long term with clinical benefits lasting decades and with restoration of normal dopaminergic innervation in the grafted striatum. In this article, we discuss the history of this field and how this has now led us to the recent stem cell trials for PwP.</p>}},
author = {{Barker, Roger A and Björklund, Anders and Parmar, Malin}},
issn = {{0265-9247}},
language = {{eng}},
month = {{07}},
publisher = {{John Wiley & Sons Inc.}},
series = {{BioEssays}},
title = {{The history and status of dopamine cell therapies for Parkinson's disease}},
url = {{https://lup.lub.lu.se/search/files/192555373/publication_in_BioEssays.pdf}},
doi = {{10.1002/bies.202400118}},
year = {{2024}},
}